Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Special Issues
2021 Year in Review - Multiple Myeloma
2021 Year in Review - Multiple Myeloma
Multiple Myeloma Year in Review Introduction
Multiple Myeloma
In 2022, the COVID-19 pandemic continues to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums.
Read More ›
Updated Analysis of the GRIFFIN Trial of Daratumumab plus RVd in Transplant-Eligible NDMM
Multiple Myeloma
Longer follow-up results of the phase 2 GRIFFIN trial demonstrated that the addition of daratumumab to RVd induction/consolidation in conjunction with ASCT, followed by 24 months of daratumumab-lenalidomide maintenance resulted in deep and durable responses, including stringent CR and MRD negativity rates, in patients with transplant-eligible NDMM.
Read More ›
Updated Results from the CARTITUDE-1 Study of Ciltacabtagene Autoleucel CAR T-Cell Therapy in RRMM
Multiple Myeloma
Results of the 18-month follow-up of the phase 1b/2 CARTITUDE-1 trial indicated that a single infusion of cilta-cel produced early, deep, and durable responses in heavily pretreated patients with RRMM, with manageable toxicity.
Read More ›
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd), Autologous Transplantation, and MRD Response–Adapted Treatment Modification in NDMM
Multiple Myeloma
These results indicate that quadruplet induction therapy with daratumumab plus carfilzomib, lenalidomide, and dexamethasone (D-KRd); ASCT; and MRD response–adapted D-KRd consolidation therapy yielded high MRD negativity rates in patients with NDMM.
Read More ›
Longer-Term Outcomes with Single-Agent Belantamab Mafodotin in Patients with RRMM: 13-Month Follow-Up from the Pivotal DREAMM-2 Study
Multiple Myeloma
Longer-term data from the DREAMM-2 trial confirmed the sustained clinical activity of the anti–B-cell maturation antigen antibody–drug conjugate belantamab mafodotin in heavily pretreated patients with RRMM, with no emergence of new safety signals.
Read More ›
International Myeloma Working Group Recommendations for the Treatment of Patients with RRMM
Multiple Myeloma
The International Myeloma Working Group developed evidence-based clinical practice recommendations for the treatment of RRMM, with the goal to help guide real-world clinical practice and improve patient outcomes.
Read More ›
Results of the Phase 3 GMMG-HD7 Trial of Isatuximab plus Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Transplant-Eligible NDMM
Multiple Myeloma
Initial primary analysis results of the ongoing phase 3 GMMG-HD7 trial demonstrated that the addition of isatuximab to the standard-of-care RVd regimen was associated with superior MRD negativity rates after induction, and the regimen was not accompanied by emergence of new safety signals or early discontinuation.
Read More ›
Updated Results from CARTITUDE-2 Trial of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Patients with Progressive MM After 1 to 3 Previous Lines of Therapy
Multiple Myeloma
In the CARTITUDE-2 cohort A that included patients with MM who had received 1 to 3 previous lines of therapy and were lenalidomide-refractory, a single infusion of cilta-cel CAR T-cell therapy produced early and deep responses, with a manageable safety profile.
Read More ›
MAIA Trial Results of Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in NDMM
Multiple Myeloma
Interim analysis results of the phase 3 MAIA trial demonstrated that frontline daratumumab plus lenalidomide/dexamethasone provided OS benefit compared with lenalidomide/dexamethasone in patients with NDMM ineligible for stem-cell transplantation.
Read More ›
CARDAMON Trial Results of Carfilzomib Maintenance Following Transplantation or Carfilzomib/Cyclophosphamide/Dexamethasone Consolidation for NDMM
Multiple Myeloma
Results of the CARDAMON trial indicate that, although carfilzomib maintenance was feasible and yielded higher MRD negativity rates at 6 months with ASCT than with consolidation, it was associated with a higher incidence of grade ≥3 adverse events and discontinuations after ASCT.
Read More ›
Page 1 of 3
1
2
3
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes